Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.

Item

http://www.wikidata.org/entity/Q40212000

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Determining the optimal ceftri ...... actamase confirmatory testing.

@en

type

Item

label

Determining the optimal ceftri ...... actamase confirmatory testing.

@en

prefLabel

Determining the optimal ceftri ...... actamase confirmatory testing.

@en

P1476

Determining the optimal ceftri ...... actamase confirmatory testing.

@en

P2093

Karen C Carroll

http://www.w3.org/2001/XMLSchema#string

Pranita D Tamma

http://www.w3.org/2001/XMLSchema#string

Sara E Cosgrove

http://www.w3.org/2001/XMLSchema#string

Yanjie Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Treatment of multidrug-resistant Gram-negative infections in children.

The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.

Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?

Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?

Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.

Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?

P304

2228-2230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.00716-14

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261749709

http://www.w3.org/2001/XMLSchema#string

P698

24740077

http://www.w3.org/2001/XMLSchema#string

P932

4042788

http://www.w3.org/2001/XMLSchema#string